Latest

Fennec reports Phase 2 PEDMARK data from Japan met primary endpoint at SIOP 2026

Investigator-led STS-J01 study showed lower hearing loss than a historical benchmark, with tumor responses seen in nearly all evaluable patients.

SEC filing